Turn Therapeutics (NASDAQ:TTRX) Stock Rating Lowered by Wall Street Zen

Turn Therapeutics (NASDAQ:TTRX) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Sunday, Wall Street Zen reports.

Other equities research analysts also recently issued research reports about the stock. Weiss Ratings downgraded shares of Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 18th. LADENBURG THALM/SH SH upgraded shares of Turn Therapeutics to a “strong-buy” rating in a research note on Monday, July 20th. Lucid Cap Mkts raised shares of Turn Therapeutics to a “strong-buy” rating in a report on Thursday, September 24th. WBB Securities reaffirmed a “sell” rating and set a $10.00 price objective on shares of Turn Therapeutics in a report on Monday, September 14th. Finally, Zacks Research upgraded shares of Turn Therapeutics to a “hold” rating in a research report on Tuesday, July 21st. Two analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $9.00.

Turn Therapeutics Trading Up 1.6%

Shares of NASDAQ:TTRX opened at $10.74 on Friday. Turn Therapeutics has a 1-year low of $2.57 and a 1-year high of $16.45. The business’s 50 day moving average is $11.62 and its 200-day moving average is $7.98. The company has a debt-to-equity ratio of 8.83, a current ratio of 1.19 and a quick ratio of 1.19.

Turn Therapeutics (NASDAQ:TTRX) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.20) earnings per share (EPS) for the quarter. As a group, sell-side analysts expect that Turn Therapeutics will post -0.40 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. SteelPeak Wealth LLC increased its holdings in shares of Turn Therapeutics by 0.7% in the third quarter. SteelPeak Wealth LLC now owns 251,275 shares of the company’s stock valued at $3,616,000 after purchasing an additional 1,819 shares in the last quarter. TD Waterhouse Canada Inc. acquired a new position in Turn Therapeutics during the 3rd quarter worth $40,000. Bank of America Corp DE acquired a new position in Turn Therapeutics during the 2nd quarter worth $103,000. Jefferies Financial Group Inc. bought a new position in Turn Therapeutics in the 2nd quarter valued at $119,000. Finally, DDFG Inc boosted its position in Turn Therapeutics by 34.9% in the 1st quarter. DDFG Inc now owns 70,534 shares of the company’s stock valued at $226,000 after buying an additional 18,246 shares during the last quarter.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.